Preliminary study on the effects of enrofloxacin, flunixin meglumine and pegbovigrastim on Mycoplasma bovis pneumonia.
Adjuvants, Immunologic
/ therapeutic use
Animals
Anti-Bacterial Agents
/ therapeutic use
Anti-Inflammatory Agents, Non-Steroidal
/ therapeutic use
Cattle
Cattle Diseases
/ drug therapy
Clonixin
/ analogs & derivatives
Drug Therapy, Combination
/ veterinary
Enrofloxacin
/ therapeutic use
Female
Granulocyte Colony-Stimulating Factor
/ therapeutic use
Mycoplasma Infections
/ drug therapy
Mycoplasma bovis
/ drug effects
Pneumonia
/ drug therapy
Recombinant Proteins
/ therapeutic use
Cattle
Flunixin
Fluoroquinolones
Mycoplasma bovis
Pegbovigrastim
Journal
BMC veterinary research
ISSN: 1746-6148
Titre abrégé: BMC Vet Res
Pays: England
ID NLM: 101249759
Informations de publication
Date de publication:
26 Oct 2019
26 Oct 2019
Historique:
received:
22
02
2019
accepted:
09
10
2019
entrez:
28
10
2019
pubmed:
28
10
2019
medline:
23
2
2020
Statut:
epublish
Résumé
Mycoplasma bovis is a causative agent of disease in cattle causing many clinical conditions. Currently there are no commercial M. bovis vaccines in Europe and treatment is difficult with decreased antimicrobial susceptibility of M. bovis field isolates. Using an M. bovis calf infection model the effectiveness of enrofloxacin given alone; in combination with flunixin meglumine, a nonsteroidal anti-inflammatory drug; and a group with an additional treatment of pegbovigrastim, an immunostimulator, was evaluated. Enrofloxacin given alone stimulated a strong immune response, reduced the clinical manifestation and lung lessions of the M. bovis infection. In contrast the combination therapy appeared ineffective. In this experiment enrofloxacin given alone appeared to be the most effective treatment of the M. bovis affected calves, whereas co-administration with flunixin meglumine, and pegbovigrastim was not beneficial in this trial.
Sections du résumé
BACKGROUND
BACKGROUND
Mycoplasma bovis is a causative agent of disease in cattle causing many clinical conditions. Currently there are no commercial M. bovis vaccines in Europe and treatment is difficult with decreased antimicrobial susceptibility of M. bovis field isolates. Using an M. bovis calf infection model the effectiveness of enrofloxacin given alone; in combination with flunixin meglumine, a nonsteroidal anti-inflammatory drug; and a group with an additional treatment of pegbovigrastim, an immunostimulator, was evaluated.
RESULTS
RESULTS
Enrofloxacin given alone stimulated a strong immune response, reduced the clinical manifestation and lung lessions of the M. bovis infection. In contrast the combination therapy appeared ineffective.
CONCLUSIONS
CONCLUSIONS
In this experiment enrofloxacin given alone appeared to be the most effective treatment of the M. bovis affected calves, whereas co-administration with flunixin meglumine, and pegbovigrastim was not beneficial in this trial.
Identifiants
pubmed: 31655595
doi: 10.1186/s12917-019-2122-3
pii: 10.1186/s12917-019-2122-3
pmc: PMC6815429
doi:
Substances chimiques
Adjuvants, Immunologic
0
Anti-Bacterial Agents
0
Anti-Inflammatory Agents, Non-Steroidal
0
Recombinant Proteins
0
Granulocyte Colony-Stimulating Factor
143011-72-7
Enrofloxacin
3DX3XEK1BN
pegbovigrastim
87M3B1263R
flunixin meglumine
8Y3JK0JW3U
Clonixin
V7DXN0M42R
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
371Subventions
Organisme : Krajowy Naukowy Osrodek Wiodacy
ID : 05-1/KNOW2/2015
Références
Res Vet Sci. 2003 Apr;74(2):105-12
pubmed: 12589733
J Dairy Sci. 2014;97(8):4842-51
pubmed: 24881799
J Proteomics. 2012 Jul 19;75(14):4207-31
pubmed: 22521269
Acta Vet Hung. 2015 Jun;63(2):167-78
pubmed: 26051255
Vet Rec. 2014 Apr 26;174(17):430
pubmed: 24603464
PLoS One. 2014 Feb 04;9(2):e87672
pubmed: 24503775
Vaccine. 2016 Jun 8;34(27):3051-3058
pubmed: 27156637
Vet Microbiol. 2017 May;204:188-193
pubmed: 28532800
Cornell Vet. 1990 Apr;80(2):173-86
pubmed: 2180631
BMC Vet Res. 2014 Oct 25;10:256
pubmed: 25344297
Vaccine. 2002 Oct 4;20(29-30):3569-75
pubmed: 12297403
Vet Rec. 2014 Nov 15;175(19):486
pubmed: 25185107
BMC Vet Res. 2015 Dec 03;11:297
pubmed: 26634824